Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Sells 8,000 Shares of Stock

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $54.85, for a total transaction of $438,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ:TRHC opened at $54.78 on Monday. The business’s 50-day simple moving average is $49.52. The company has a quick ratio of 1.73, a current ratio of 1.80 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare Inc has a one year low of $40.86 and a one year high of $91.16. The company has a market cap of $1.20 billion, a PE ratio of 161.12 and a beta of 1.62.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). The firm had revenue of $60.96 million for the quarter, compared to analysts’ expectations of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. As a group, research analysts expect that Tabula Rasa HealthCare Inc will post -0.55 EPS for the current year.

Several equities research analysts recently commented on TRHC shares. Piper Jaffray Companies boosted their price objective on shares of Beigene to $180.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research report on Friday, July 12th. ValuEngine raised shares of Zillow Group from a “hold” rating to a “buy” rating in a research report on Thursday, July 11th. Guggenheim assumed coverage on shares of Patterson Companies in a research report on Wednesday, April 17th. They set a “neutral” rating and a $23.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of CytomX Therapeutics in a research report on Monday, May 13th. They set an “overweight” rating and a $21.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $82.12.

Several institutional investors have recently added to or reduced their stakes in TRHC. First Mercantile Trust Co. increased its stake in shares of Tabula Rasa HealthCare by 64.5% during the 1st quarter. First Mercantile Trust Co. now owns 995 shares of the company’s stock worth $56,000 after purchasing an additional 390 shares during the last quarter. South Dakota Investment Council acquired a new position in shares of Tabula Rasa HealthCare during the 1st quarter worth about $141,000. Belpointe Asset Management LLC acquired a new position in shares of Tabula Rasa HealthCare during the 1st quarter worth about $172,000. LS Investment Advisors LLC increased its stake in shares of Tabula Rasa HealthCare by 11.2% during the 1st quarter. LS Investment Advisors LLC now owns 3,129 shares of the company’s stock worth $177,000 after purchasing an additional 316 shares during the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new position in shares of Tabula Rasa HealthCare during the 1st quarter worth about $212,000. Institutional investors own 85.92% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Story: Key terms to understand channel trading

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.